DrugDashboards

Market view

guaifenesin, phenylephrine hcl · Syrup

0 marketed package NDCs · 0 makers active in the last 30 days

Not counted: 1 NDC no longer in the directory.

ⓘ How this was built
Data sources
  • FDA NDC Directory (openFDA), read daily — package listings, marketing category, labeler
  • DailyMed SPL establishment roles + name patterns → derived.labeler_kinds (repackager classification)
Method

Marketed package NDCs are listings for this exact FDA generic-name string (and dosage form, when one is selected) that are in the current directory file and are finished products — bulk ingredients, export-only and further-processing listings are excluded and counted separately. Makers are distinct labeler names seen in the last 30 days minus classified repackagers/relabelers; a listing is not proof of shipping volume. To check: search the generic name in FDA's NDC Directory and count labelers.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Same molecule, listed under other names (separate rosters and prices): guaifenesin and phenylephrine hcl (3 NDCs)

All formsTablet (3)Tablet, Film Coated (2)Solution/ Drops (1)

What changed in the last 90 days

Every detected change for guaifenesin, phenylephrine hcl, newest first — price moves, shortages, recalls, and labelers entering or leaving. Detected by comparing each day’s federal data against what we already held.

ⓘ How this was built
Data sources
  • DrugDashboards change feed — daily diffs of the NDC Directory, NADAC, FDA shortages and enforcement reports, Part D formularies
Method

Events whose NDC belongs to a product with this generic-name string, dated by the day the change was detected (the file's own effective date is shown on price rows). Generic NADAC is a 3-month moving average since December 2024, so most price moves here are small and lag the market.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Same drug class

Other molecules FDA puts in Expectorant, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.

ⓘ How this was built
Data sources
  • FDA NDC Directory pharmacologic class (EPC) per product
  • FDA drug shortages (openFDA)
  • FDA NDC Directory labelers + derived.labeler_kinds
Method

Peers share this drug's most common Established Pharmacologic Class. 'In shortage' means an FDA Current row whose NDC belongs to that molecule or whose listing name normalizes to it (any presentation). Maker counts are labelers active in the last 30 days minus repackagers, across all forms.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Common questions

Is Guaifenesin, phenylephrine hcl in shortage right now?
No. FDA's shortage list has no current entry for Guaifenesin, phenylephrine hcl under this name or its presentations. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
Who makes Guaifenesin, phenylephrine hcl?
5 companies have listed Guaifenesin, phenylephrine hcl in the FDA NDC Directory in the last 30 days. A listing is not proof of volume; the products below show every listed package.
What does Guaifenesin, phenylephrine hcl cost?
The typical pharmacy pays about $0.0903 per unit for Guaifenesin, phenylephrine hcl — the median of 1 package NDCs' latest CMS NADAC prices (last 6 months, unit-priced products only). That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.
ⓘ How this was built
Data sources
  • FDA drug shortages (openFDA)
  • FDA NDC Directory + derived.labeler_kinds
  • CMS NADAC weekly file
Method

Shortage: any Current FDA row whose package NDC belongs to this generic-name string or whose listing name normalizes to the same molecule; the presentations named are those rows. Makers: distinct labelers listing this string in the last 30 days, repackagers excluded. Cost: the median of each NDC's most recent NADAC within 6 months, restricted to the market's most common billing unit and to the generic cohort when one exists.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

All marketed products

0 marketed NDCs, every one listed. NADAC prices show the file date; prices older than 6 months are greyed.

ⓘ How this was built
Data sources
  • FDA NDC Directory (openFDA) — products, packages, labelers, marketing category, TE code (application-level)
  • CMS NADAC — each NDC's latest price
  • DrugDashboards fragility v1 score
Method

Finished products currently in the NDC Directory under this generic-name string (bulk, export-only and further-processing listings excluded). 'Widely marketed' marks the four form/strength/package combinations with the most NADAC-priced NDCs — a proxy for retail availability, not dispensing volume. Labeler counts in the tree include repackagers, marked in the roster on each drug page.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

No finished products are currently listed under this name.